Yissum teams with medical cannabis co PhytoTech

The Hebrew University tech transfer company will collaborate on a novel delivery system.

Hebrew University of Jerusalem technology transfer company Yissum Research Development Co. Ltd. has signed an exclusive licensing and collaboration agreement with PhytoTech Medical Ltd. for the development, manufacturing and marketing of a novel delivery system to enhance the bioavailability of cannabidiol (CBD) and/or THC. These are the active ingredients in cannabis, for the treatment of various medical indications. The novel formulations are based on oral and transbuccal delivery technologies developed by Professors Abraham Domb and Amnon Hoffman of the Hebrew University Faculty of Medicine, School of Pharmacy, Institute of Drug Research.

PhytoTech Medical last week became the first medical marijuana company on the Australian Securities Exchange (ASX). The company raised AUS$5.9 million dollars (US$4.7 million) at a share price of $0.20 per share.

Cannabis based medications are currently in clinical use worldwide. The most known formulation is...

Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.